-
1 Comment
Amedisys, Inc is currently in a long term uptrend where the price is trading 1.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Amedisys, Inc's total revenue rose by 10.0% to $551M since the same quarter in the previous year.
Its net income has increased by 63.3% to $45M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.7% to $64M since the same quarter in the previous year.
Based on the above factors, Amedisys, Inc gets an overall score of 4/5.
Industry | Medical Care Facilities |
---|---|
Sector | Healthcare |
Exchange | F |
CurrencyCode | EUR |
ISIN | US0234361089 |
Beta | 0.89 |
---|---|
Market Cap | 3B |
PE Ratio | 70.61 |
Target Price | 230.13 |
Dividend Yield | None |
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ADY.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025